A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation

TAÇYILDIZ N., Tanyildiz H. G., ÜNAL E., DİNÇASLAN H., Asarcikli F., Aksoy B. A., ...More

TURKISH JOURNAL OF PEDIATRICS, vol.61, no.5, pp.671-676, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 61 Issue: 5
  • Publication Date: 2019
  • Doi Number: 10.24953/turkjped.2019.05.005
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.671-676
  • Keywords: Hodgkin lymphoma, brentuximab vedotin, EXPERIENCE, RISK, MULTICENTER, PROGRAM, SGN-35, CD30
  • Istanbul University Affiliated: No


Hodgkin's lymphoma (HL) is highly curable disease in its early stages, but in advanced stages, it presents a dilemma when it becomes refractory or relapses after several rounds of chemotherapy. Brentuximab vedotin (BV) is an antibody-drug conjugate that targets the tumor necrosis receptor family protein member CD30 positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin-E. In adult and pediatric studies, it has been shown to be an effective salvage therapy for primary refractory HL or relapse after autologous stem cell transplant (ASCT).